No insider purchase over the last 90 days. The latest was filed 03 Feb 2025.
ModivCare Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for ModivCare Inc. The previous disclosure was published on 5 August 2025.
Our records for ModivCare Inc go back to 2016, with 23 purchases and 1 sale on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2024 · cache
25 of 150 declarations
ModivCare Inc. (Nasdaq: MODV) is a United States-based healthcare services company listed on the NASDAQ market in the United States and headquartered in Denver, Colorado. The company was formed in 1996 as The Providence Service Corporation and rebranded as ModivCare in 2021, signaling a shift toward a more explicit technology-enabled supportive-care model focused on improving access, coordination, and outcomes for patients covered by public and private payors. Today, ModivCare positions itself as an integrated platform serving Medicaid, managed care organizations, and other payors that need scalable support services around high-need populations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1220754/000122075425000008/modv-20241231.htm?utm_source=openai))
Historically, the company built its foundation in non-emergency medical transportation, or NEMT, an area where scale, route optimization, provider network management, and regulatory know-how matter materially. Over time, ModivCare expanded beyond transportation through a series of acquisitions that broadened its care continuum. Simplura strengthened the in-home and personal care franchise, Care Finders added to that footprint, VRI brought remote patient monitoring capabilities, and WellRyde enhanced the software layer used to orchestrate transportation services. As a result, ModivCare evolved from a transportation-centric operator into a diversified supportive-care platform spanning logistics, home-based care, and digital monitoring. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1220754/000122075425000008/modv-20241231.htm))
Its core business lines now include NEMT, personal care / in-home care, and remote patient monitoring. Strategically, the company sits at the intersection of healthcare operations and technology, aiming to connect members to care while helping payors lower avoidable utilization and improve adherence. Competitive advantages are typically described in terms of national scale, contract management expertise, technology integration, and the ability to operate across both urban and rural geographies. The company also highlights its ability to serve complex, high-need patients and to work within heavily regulated Medicaid frameworks, which can create barriers to entry for smaller providers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1220754/000122075425000008/modv-20241231.htm))
Geographically, ModivCare operates primarily in the United States, with nationwide contract coverage that varies by service line and state program. While Denver remains the corporate hub, certain acquired businesses preserve local operating bases, particularly in personal care and monitoring. In 2025, the most important recent development was the company’s comprehensive restructuring, announced in August, followed by its exit from Chapter 11 later in the year, a move designed to materially reduce debt and support ongoing operations. Earlier in 2025, management also emphasized new contract wins, automation, lower G&A, tighter working-capital discipline, and divestiture readiness. For investors, ModivCare represents a healthcare-services platform with structural demand drivers, but also elevated execution, reimbursement, and balance-sheet risk. ([investors.modivcare.com](https://investors.modivcare.com/news-and-media/news-releases/news-details/2025/Modivcare-Enters-into-Comprehensive-Restructuring-Agreement-to-Strengthen-its-Future-Reduce-Debt-and-Inject-Capital/?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2024 | 2.79 bn USD | -201.3 m USD | -14.14 USD | 10-K |
| Dec 2023 | 2.75 bn USD | -204.5 m USD | -14.43 USD | 10-K |
| Dec 2022 | 2.50 bn USD | -31.8 m USD | -2.26 USD | 10-K |
| Dec 2021 | 2.00 bn USD | -6.6 m USD | -0.47 USD | 10-K |
| Dec 2020 | 1.37 bn USD | 88.8 m USD | 2.37 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.